


SDC 1 – Combined Supplemental Digital Content

SDC 2, Table 1 - General characteristics of patients

Age at conversion (Mean $\pm$ SD) (years)	55.9 $\pm$ 13.2
Gender distribution (%) Female/Male	32.9% / 67.1%
Time from transplantation to conversion (median; P ₂₅₋₇₅) (months)	69.4 (13.7-129.9)
Number of transplant, N(%)	
First	197 (68.7%)
Second	21 (9.5%)
Third	4 (1.8%)
Preconversion immunosuppression, N (%)	
Calcineurin inhibitor	
Cyclosporine	102 (45.0)
Tacrolimus	122 (55.0)
Antimetabolite drugs	
Mycophenolate mofetilo	93 (41.9)
Mycophenolate sodium	78 (35.1)
Azathioprine	17 (7.7)
None	34 (15.3)
Prednisone	
Yes	96 (43.2)
No	126 (56.8)

SDC 1 – Combined Supplemental Digital Content

SDC 3 – Figure 1



SDC 1 – Combined Supplemental Digital Content

SDC 4 - Table 2. Comparison of everolimus levels (ng/ml) between patients with proteinuria <900 mg/d and proteinuria ≥900 mg/d one year after everolimus conversion

Time post-conversion	4 th day	8 th day	1 st month	2 nd month	3 rd month	6 th month	9 th month	1 st year
Proteinuria <900 mg/d	9.1 ± 5.6	8.4 ± 4.3	7.9 ± 3.2	7.3 ± 2.4	7.1 ± 2.3	7.2 ± 2.3	7.5 ± 3.2	7.0 ± 2.6
Proteinuria ≥900 mg/d	8.7 ± 4.9	8.5 ± 4.6	7.9 ± 3.0	7.6 ± 3.0	7.1 ± 3.1	6.7 ± 2.0	6.9 ± 2.5	6.8 ± 2.6
p	0.704	0.911	0.961	0.633	0.87	0.322	0.377	0.316